BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 22362824)

  • 1. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY.
    van der Lely AJ; Biller BM; Brue T; Buchfelder M; Ghigo E; Gomez R; Hey-Hadavi J; Lundgren F; Rajicic N; Strasburger CJ; Webb SM; Koltowska-Häggström M
    J Clin Endocrinol Metab; 2012 May; 97(5):1589-97. PubMed ID: 22362824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY.
    Freda PU; Gordon MB; Kelepouris N; Jonsson P; Koltowska-Haggstrom M; van der Lely AJ
    Endocr Pract; 2015 Mar; 21(3):264-74. PubMed ID: 25370326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The German ACROSTUDY: past and present.
    Buchfelder M; Schlaffer S; Droste M; Mann K; Saller B; Brübach K; Stalla GK; Strasburger CJ;
    Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S3-S10. PubMed ID: 19684061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY.
    Brue T; Castinetti F; Lundgren F; Koltowska-Häggström M; Petrossians P;
    Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S11-7. PubMed ID: 19684051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ACROSTUDY: the first 5 years.
    Trainer PJ
    Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S19-24. PubMed ID: 19684052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ACROSTUDY: Status Update on 469 Patients.
    Brue T
    Horm Res; 2009 Jan; 71 Suppl 1():34-8. PubMed ID: 19153503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY.
    Bernabeu I; Pico A; Venegas E; Aller J; Alvarez-Escolá C; García-Arnés JA; Marazuela M; Jonsson P; Mir N; García Vargas M;
    Pituitary; 2016 Apr; 19(2):127-37. PubMed ID: 26553421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegvisomant treatment in patients with acromegaly in clinical practice: The French ACROSTUDY.
    Chanson P; Brue T; Delemer B; Caron P; Borson-Chazot F; Zouater H;
    Ann Endocrinol (Paris); 2015 Dec; 76(6):664-70. PubMed ID: 26596374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience.
    Cannavo S; Bogazzi F; Colao A; De Marinis L; Maffei P; Gomez R; Graziano E; Monterubbianesi M; Grottoli S;
    J Endocrinol Invest; 2015 Oct; 38(10):1099-109. PubMed ID: 25916431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
    Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
    Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly.
    Neggers SJ; Franck SE; de Rooij FW; Dallenga AH; Poublon RM; Feelders RA; Janssen JA; Buchfelder M; Hofland LJ; Jørgensen JO; van der Lely AJ
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3644-52. PubMed ID: 24937542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance.
    Yamaguchi H; Shimatsu A; Okayama A; Sato T
    Endocr J; 2020 Feb; 67(2):201-210. PubMed ID: 31723069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACROSTUDY: the Italian experience.
    Grottoli S; Maffei P; Bogazzi F; Cannavò S; Colao A; Ghigo E; Gomez R; Graziano E; Monterubbianesi M; Jonsson P; De Marinis L
    Endocrine; 2015 Feb; 48(1):334-41. PubMed ID: 25150035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are there country-specific differences in the use of pegvisomant for acromegaly in clinical practice? An analysis from ACROSTUDY.
    Grottoli S; Bianchi A; Bogazzi F; Bona C; Carlsson MO; Colao A; Dassie F; Giampietro A; Gomez R; Granato S; Maffei P; Pivonello R; Prencipe N; Ragonese M; Urbani C; Cannavò S
    J Endocrinol Invest; 2022 Aug; 45(8):1535-1545. PubMed ID: 35359232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study.
    Buchfelder M; Weigel D; Droste M; Mann K; Saller B; Brübach K; Stalla GK; Bidlingmaier M; Strasburger CJ;
    Eur J Endocrinol; 2009 Jul; 161(1):27-35. PubMed ID: 19411302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis.
    Biering H; Saller B; Bauditz J; Pirlich M; Rudolph B; Johne A; Buchfelder M; Mann K; Droste M; Schreiber I; Lochs H; Strasburger CJ;
    Eur J Endocrinol; 2006 Feb; 154(2):213-20. PubMed ID: 16452533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly.
    Tritos NA; Biller BM
    Pituitary; 2017 Feb; 20(1):129-135. PubMed ID: 27631335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly.
    Neggers SJ; van Aken MO; Janssen JA; Feelders RA; de Herder WW; van der Lely AJ
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4598-601. PubMed ID: 17895318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY.
    Fleseriu M; Führer-Sakel D; van der Lely AJ; De Marinis L; Brue T; van der Lans-Bussemaker J; Hey-Hadavi J; Camacho-Hubner C; Wajnrajch MP; Valluri SR; Palladino AA; Gomez R; Salvatori R
    Eur J Endocrinol; 2021 Aug; 185(4):525-538. PubMed ID: 34342594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant.
    Strasburger CJ; Mattsson A; Wilton P; Aydin F; Hey-Hadavi J; Biller BMK
    Eur J Endocrinol; 2018 Apr; 178(4):321-329. PubMed ID: 29371335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.